Skip to content
Search

Latest Stories

MHRA imposes restrictions on stimulant laxatives sale

The Medicines and Healthcare products Regulatory Agency (MHRA) has introduced new restrictions on the sale of stimulant laxatives to counter risks from overuse.

People who take stimulant laxatives for constipation will now be supplied in smaller packs, with on-pack overuse warnings.


The new packs will begin to appear in stores over the summer. Additional label warnings make clear that stimulant laxatives do not help with weight loss.

Dr Sarah Branch, director of MHRA’s vigilance and risk management of medicines division, said: "Stimulant laxatives can provide short-term relief to some people with occasional constipation, and most people use these medicines safely. However, there is evidence of misuse by people with eating disorders, and of long-term use by the elderly, as well as inappropriate use in children."

The regulator added that the long overuse of stimulant laxatives (including products containing bisacodyl, senna or sodium picosulfate) can result in damage to the digestive system.

Parents and carers can talk to a pharmacist about treatment of short-term constipation in children over 12.

However, they should seek advice from a prescriber such as their GP if the child is younger than 12 years or they are worried about their child’s health.

Commenting on the MHRA’s latest move, Sandra Gidley, president of Royal Pharmaceutical Society, said: “Misusing laxatives can have a serious impact on the health of patients and the new risk minimisation measures will improve patient safety. We’re pleased to have worked with the MHRA on new guidance for community pharmacists and their teams so they can give patients the best advice.

“As experts in medicines, pharmacists are well placed to help ensure patients do not overuse stimulant laxatives. If a patient has a question about different laxative products or are unsure about what they are currently taking, the pharmacy team will be able to help and signpost on if necessary.”

The new guidelines restrict the use of stimulant laxatives sold in retail outlets to patients over the age of 18. Pharmacists will be able to sell stimulant laxatives for use in children aged 12 and over.

More For You

Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less
NICE approves once-daily tablet Linzagolix for endometriosis

NICE recommends Linzagolix with add-back therapy for endometriosis

Image credit: Getty Images

NICE approves new at-home treatment for endometriosis

The National Institute for Health and Care Excellence (NICE) has recommended Linzagolix (brand name Yselty), a once-daily tablet, as a new treatment option for endometriosis.

Developed by Theramex, Linzagolix is approved for use alongside hormonal add-back therapy in adults of reproductive age who have previously tried other medical or surgical treatments for the condition.

Keep ReadingShow less